Related Experiment Videos
Protecting the endometrium. Opposing the hyperplasia/malignancy potential of ERT
W E Gibbons1, I H Thorneycroft
1Department of Obstetrics and Gynecology, Eastern Virginia Medical School, 601 Colley Avenue, Suite 229, Norfolk, VA 23507-1627, USA.
The Journal of Reproductive Medicine
|June 8, 2001
Summary
Long-term progestogen therapy effectively protects the endometrium during hormone replacement therapy. Duration of use is more impactful than dosage for preventing hyperplasia and adenocarcinoma.
Area of Science:
- Gynecology
- Endocrinology
- Oncology
Background:
- Hormone replacement therapy (HRT) combinations are evaluated for endometrial protection.
- Minimizing hyperplasia and adenocarcinoma risk is a key objective in HRT research.
Purpose of the Study:
- To review clinical and histologic effects of HRT combinations.
- To determine optimal progestogen therapy for endometrial protection.
Main Methods:
- Review of multiple clinical trials on HRT.
- Analysis of progestogen dose and duration effects on the endometrium.
Main Results:
- High-dose, long-term progestogen therapy is effective in endometrial protection.
- Progestogen therapy duration impacts endometrial protection more than dose.
- Specific regimen recommendations provided for conjugated equine estrogen (CEE) users.
Conclusions:
- Long-term progestogen therapy is crucial for endometrial safety in HRT.
- Sequential and continuous combined regimens require specific progestogen types and durations for efficacy.